Mount Sinai's Knowledge Management Center for Illuminating the Druggable Genome

西奈山阐明可药物基因组的知识管理中心

• 批准号: 9558160
• 负责人: Joel Thomas Dudley
• 金额: $ 6.6万
• 依托单位: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-08-01 至 2018-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9558160
• 关键词: Adverse effects; Attenuated; Collaborations; Data; Disease; Fibrosis; Foundations; Gene Targeting; Genome; Information Resources Management; Investigation; Ion Channel; Kidney; Link; Literature; Molecular and Cellular Biology; Nuclear Receptors; Patients; Pharmaceutical Preparations; Positioning Attribute; Productivity; Protein Family; Protein Kinase; Research; Source; Source Code; Tertiary Protein Structure; Validation; base; disease phenotype; individual patient; innovation

DESCRIPTION: The Knowledge Management Center for Illuminating the Druggable Genome (KMC-IDG) at Mount Sinai will assemble, organize and visualize data collected from the under-studied druggable genome from the four families: protein kinases, nuclear receptor, ion channels and GPCRs. The KMC-IDG will also attempt linking such under-studied druggable targets for their potential applications in various diseases. To achieve this we will assemble and abstract data from four domains: proteins/genes/targets, drugs/perturbagens, diseases/phenotypes/side-effects, and data from individual patients. Various pipe-lines and workflow will be established to connect clusters of patients from various diseases to under-studied druggable targets. The Ma'ayan and Dudley Labs are well positioned to carry out successfully this project based on their prior track record of productivity, foundation of source code and data that is already collected and organized, and strong existing user base that can be directed to the newly developed portal. In addition, both labs have a strong track record of collaborations including the computational identification and experimental validation of at least one under-studied protein kinase as a potential important target for attenuating kidney fibrosis. One unique and innovative research component of this project is an investigation into the sources of the literature and experimental biases that exist in the molecular and cellular biology research domains.

产品说明： 位于西奈山的可药用基因组照明知识管理中心（KMC-IDG）将收集、组织和可视化从四个家族（蛋白激酶、核受体、离子通道和GPCR）中未研究的可药用基因组收集的数据。KMC-IDG还将尝试将这些研究不足的可药用靶标与其在各种疾病中的潜在应用联系起来。为了实现这一目标，我们将从四个领域收集和提取数据：蛋白质/基因/靶标，药物/干扰物，疾病/表型/副作用，以及来自个体患者的数据。将建立各种管道和工作流程，以将各种疾病的患者群与正在研究的药物靶点联系起来。Ma'ayan实验室和达德利实验室有能力成功地执行这个项目，因为它们以前的生产率记录、源代码和已经收集和组织的数据的基础以及可以定向到新开发的门户的强大的现有用户基础。此外，这两个实验室都有很好的合作记录，包括至少一种研究不足的蛋白激酶的计算鉴定和实验验证，作为减轻肾纤维化的潜在重要靶点。该项目的一个独特和创新的研究组成部分是对分子和细胞生物学研究领域中存在的文献和实验偏差的来源进行调查。